In Vitro Analysis of AKR1D1 Interactions with Clopidogrel: Effects on Enzyme Activity and Gene Expression

1. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14;37(3):267–315. Roffi M Patrono C Collet JP Mueller C Valgimigli M Andreotti F 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) . Eur Heart J . 2016 Jan 14 ; 37 ( 3 ): 267 – 315 . Search in Google Scholar

2. Geisler T, Schaeffeler E, Dippon J, Winter S, Buse V, Bischofs C, et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacog-enomics. 2008 Sep;9(9):1251–9. Geisler T Schaeffeler E Dippon J Winter S Buse V Bischofs C CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation . Pharmacog-enomics . 2008 Sep ; 9 ( 9 ): 1251 – 9 . Search in Google Scholar

3. Qu J, Zhang H, Rao C, Chen S, Zhao Y, Sun H, et al. Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery. J Am Heart Assoc. 2021 Jun;10(11):e020413. Qu J Zhang H Rao C Chen S Zhao Y Sun H Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery . J Am Heart Assoc . 2021 Jun ; 10 ( 11 ): e020413 . Search in Google Scholar

4. Tan BEX, Wong PY, Baibhav B, Thakkar S, Azhar AZ, Rao M, et al. Clopidogrel Vs Aspirin Monotherapy Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. Current Problems in Cardiology. 2023 Aug 1;48(8):101174. Tan BEX Wong PY Baibhav B Thakkar S Azhar AZ Rao M Clopidogrel Vs Aspirin Monotherapy Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis . Current Problems in Cardiology . 2023 Aug 1 ; 48 ( 8 ): 101174 . Search in Google Scholar

5. Gurbel PA, Tantry US. Clopidogrel resistance? Thromb Res. 2007;120(3):311–21. Gurbel PA Tantry US. Clopidogrel resistance? Thromb Res . 2007 ; 120 ( 3 ): 311 – 21 . Search in Google Scholar

6. Hawken TN, Berenson AM, Klopfenstein J, Leithead CC, Brinster CJ, Sternbergh WC, et al. Clopidogrel Resistance Is Common in Patients Undergoing Vascular and Coronary Interventions. Journal of Vascular Surgery. 2021 Jan 1;73(1):e25–6. Hawken TN Berenson AM Klopfenstein J Leithead CC Brinster CJ Sternbergh WC Clopidogrel Resistance Is Common in Patients Undergoing Vascular and Coronary Interventions . Journal of Vascular Surgery . 2021 Jan 1 ; 73 ( 1 ): e25 – 6 . Search in Google Scholar

7. Ma TKW, Lam YY, Tan VP, Yan BP. Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? British Journal of Clinical Pharmacology. 2011 Oct;72(4):697. Ma TKW Lam YY Tan VP Yan BP. Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? British Journal of Clinical Pharmacology . 2011 Oct ; 72 ( 4 ): 697 . Search in Google Scholar

8. Ray S. Clopidogrel resistance: The way forward. Indian Heart Journal. 2014 Sep;66(5):530. Ray S. Clopidogrel resistance: The way forward . Indian Heart Journal . 2014 Sep ; 66 ( 5 ): 530 . Search in Google Scholar

9. Giantini A, Timan IS, Dharma R, Sukmawan R, Setiabudy R, Alwi I, et al. The role of clopidogrel resistance-related genetic and epigenetic factors in major adverse cardiovascular events among patients with acute coronary syndrome after percutaneous coronary intervention. Frontiers in Cardiovascular Medicine. 2023 Feb 8;9:1027892. Giantini A Timan IS Dharma R Sukmawan R Setiabudy R Alwi I The role of clopidogrel resistance-related genetic and epigenetic factors in major adverse cardiovascular events among patients with acute coronary syndrome after percutaneous coronary intervention . Frontiers in Cardiovascular Medicine . 2023 Feb 8 ; 9 : 1027892 . Search in Google Scholar

10. Sangkuhl K, Klein TE, Altman RB. Clopidogrel pathway. Pharmacogenetics and Genomics. 2010 Jul;20(7):463. Sangkuhl K Klein TE Altman RB. Clopidogrel pathway . Pharmacogenetics and Genomics . 2010 Jul ; 20 ( 7 ): 463 . Search in Google Scholar

11. Savi P, Herbert JM, Pflieger AM, Dol F, Delebassee D, Combalbert J, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochemical Pharmacology. 1992 Aug 4;44(3):527–32. Savi P Herbert JM Pflieger AM Dol F Delebassee D Combalbert J Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel . Biochemical Pharmacology . 1992 Aug 4 ; 44 ( 3 ): 527 – 32 . Search in Google Scholar

12. Jiang XL, Samant S, Lesko LJ, Schmidt S. Clinical pharmacokinetics and pharmacodynamics of clopi-dogrel. Clin Pharmacokinet. 2015 Feb;54(2):147–66. Jiang XL Samant S Lesko LJ Schmidt S. Clinical pharmacokinetics and pharmacodynamics of clopi-dogrel . Clin Pharmacokinet . 2015 Feb ; 54 ( 2 ): 147 – 66 . Search in Google Scholar

13. Pan Y, Chen W, Xu Y, Yi X, Han Y, Yang Q, et al. Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack. Circulation. 2017 Jan 3;135(1):21–33. Pan Y Chen W Xu Y Yi X Han Y Yang Q Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack . Circulation . 2017 Jan 3 ; 135 ( 1 ): 21 – 33 . Search in Google Scholar

14. Hou X, Shi J, Sun H. Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis. Eur J Clin Pharmacol. 2014 Sep;70(9):1041–7. Hou X Shi J Sun H. Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis . Eur J Clin Pharmacol . 2014 Sep ; 70 ( 9 ): 1041 – 7 . Search in Google Scholar

15. Ford NF. The Metabolism of Clopidogrel: CY-P2C19 Is a Minor Pathway. J Clin Pharmacol. 2016 Dec;56(12):1474–83. Ford NF. The Metabolism of Clopidogrel: CY-P2C19 Is a Minor Pathway . J Clin Pharmacol . 2016 Dec ; 56 ( 12 ): 1474 – 83 . Search in Google Scholar

16. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics. 2013 Apr 1;138(1):103–41. Zanger UM Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation . Pharmacology & Therapeutics . 2013 Apr 1 ; 138 ( 1 ): 103 – 41 . Search in Google Scholar

17. Barski OA, Tipparaju SM, Bhatnagar A. The aldoketo reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev. 2008;40(4):553–624. Barski OA Tipparaju SM Bhatnagar A. The aldoketo reductase superfamily and its role in drug metabolism and detoxification . Drug Metab Rev . 2008 ; 40 ( 4 ): 553 – 624 . Search in Google Scholar

18. Nikolaou N, Gathercole LL, Kirkwood L, Dunford JE, Hughes BA, Gilligan LC, et al. AKR1D1 regulates glucocorticoid availability and glucocorticoid receptor activation in human hepatoma cells. The Journal of Steroid Biochemistry and Molecular Biology. 2019 May 1;189:218–27. Nikolaou N Gathercole LL Kirkwood L Dunford JE Hughes BA Gilligan LC AKR1D1 regulates glucocorticoid availability and glucocorticoid receptor activation in human hepatoma cells . The Journal of Steroid Biochemistry and Molecular Biology . 2019 May 1 ; 189 : 218 – 27 . Search in Google Scholar

19. Penning TM, Wangtrakuldee P, Auchus RJ. Structural and Functional Biology of Aldo-Keto Reductase Steroid-Transforming Enzymes. Endocr Rev. 2019 Apr 1;40(2):447–75. Penning TM Wangtrakuldee P Auchus RJ. Structural and Functional Biology of Aldo-Keto Reductase Steroid-Transforming Enzymes . Endocr Rev . 2019 Apr 1 ; 40 ( 2 ): 447 – 75 . Search in Google Scholar

20. Chen M, Penning TM. 5β-Reduced steroids and human Δ(4)-3-ketosteroid 5β-reductase (AKR1D1). Steroids. 2014 May;83:17–26. Chen M Penning TM. 5β-Reduced steroids and human Δ(4)-3-ketosteroid 5β-reductase (AKR1D1) . Steroids . 2014 May ; 83 : 17 – 26 . Search in Google Scholar

21. Chaudhry AS, Thirumaran RK, Yasuda K, Yang X, Fan Y, Strom SC, et al. Genetic Variation in AldoKeto Reductase 1D1 (AKR1D1) Affects the Expression and Activity of Multiple Cytochrome P450s. Drug Metab Dispos. 2013 Aug;41(8):1538–47. Chaudhry AS Thirumaran RK Yasuda K Yang X Fan Y Strom SC Genetic Variation in AldoKeto Reductase 1D1 (AKR1D1) Affects the Expression and Activity of Multiple Cytochrome P450s . Drug Metab Dispos . 2013 Aug ; 41 ( 8 ): 1538 – 47 . Search in Google Scholar

22. Kapedanovska-Nestorovska A, Dimovski AJ, Sterjev Z, Matevska Geskovska N, Suturkova L, Ugurov P, et al. The AKR1D1*36 (rs1872930) Allelic Variant Is Independently Associated With Clopidogrel Treatment Outcome. Pharmgenomics Pers Med. 2019 Oct; 12:287–95. Kapedanovska-Nestorovska A Dimovski AJ Sterjev Z Matevska Geskovska N Suturkova L Ugurov P The AKR1D1*36 (rs1872930) Allelic Variant Is Independently Associated With Clopidogrel Treatment Outcome . Pharmgenomics Pers Med . 2019 Oct ; 12 : 287 – 95 . Search in Google Scholar

23. Green MR, Sambrook J. Molecular Cloning: A Laboratory Manual. 4th ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2012. Green MR Sambrook J. Molecular Cloning: A Laboratory Manual . 4 th ed. Cold Spring Harbor (NY) : Cold Spring Harbor Laboratory Press ; 2012 . Search in Google Scholar

24. Brown TA. Gene Cloning and DNA Analysis: An Introduction. 8th ed. Hoboken (NJ): Wiley-Blackwell; 2020. Brown TA. Gene Cloning and DNA Analysis: An Introduction . 8 th ed. Hoboken (NJ) : Wiley-Blackwell ; 2020 . Search in Google Scholar

25. Shutevska K, Nestorovska AK. Cloning, expression, and purification of recombinant AKR1D1 for therapeutic applications. Acta Pharm. 2024 Dec 17; doi: 10.2478/acph-2025-0003. Online ahead of print. Shutevska K Nestorovska AK. Cloning, expression, and purification of recombinant AKR1D1 for therapeutic applications . Acta Pharm . 2024 Dec 17 ; doi: 10.2478/acph-2025-0003 . Online ahead of print. Open DOISearch in Google Scholar

26. Möller G, Temml V, Cala Peralta A, Gruet O, Rich-omme P, Séraphin D, et al. Analogues of Natural Chalcones as Efficient Inhibitors of AKR1C3. Metabolites. 2022 Feb;12(2):99. Möller G Temml V Cala Peralta A Gruet O Rich-omme P Séraphin D Analogues of Natural Chalcones as Efficient Inhibitors of AKR1C3 . Metabolites . 2022 Feb ; 12 ( 2 ): 99 . Search in Google Scholar

27. Nikolaou N, Gathercole LL, Marchand L, Althari S, Dempster NJ, Green CJ, et al. AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease. Metabolism. 2019 Oct;99:67–80. Nikolaou N Gathercole LL Marchand L Althari S Dempster NJ Green CJ AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease . Metabolism . 2019 Oct ; 99 : 67 – 80 . Search in Google Scholar

28. Kędzierski J, Allard JA, Odermatt A, Smieško M. Assessment of the inhibitory potential of anabolic steroids towards human AKR1D1 by computational methods and in vitro evaluation. Toxicology Letters. 2023 Aug 1;384:1–13. Kędzierski J Allard JA Odermatt A Smieško M. Assessment of the inhibitory potential of anabolic steroids towards human AKR1D1 by computational methods and in vitro evaluation . Toxicology Letters . 2023 Aug 1 ; 384 : 1 – 13 . Search in Google Scholar

29. Laurence L. Brunton, Randa Hilal-Dandan, Bjorn Knollmann, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 13th ed. New York, NY, USA: McGraw Hill Education, 2017. Laurence L. Brunton Randa Hilal-Dandan Bjorn Knollmann , editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics . 13 th ed. New York, NY, USA : McGraw Hill Education , 2017 . Search in Google Scholar

30. Rižner TL, Penning TM. Role of Aldo-Keto Reductase Family 1 (AKR1) Enzymes in Human Steroid Metabolism. Steroids. 2013 Nov 1;79:10.1016/j.ster-oids.2013.10.012. Rižner TL Penning TM. Role of Aldo-Keto Reductase Family 1 (AKR1) Enzymes in Human Steroid Metabolism . Steroids . 2013 Nov 1 ; 79 : 10.1016/j.ster-oids.2013.10.012 . Open DOISearch in Google Scholar

31. Chen M, Drury JE, Penning TM. Substrate specificity and inhibitor analyses of human steroid 5β-reductase (AKR1D1). Steroids. 2011 Apr;76(5):484–90. Chen M Drury JE Penning TM. Substrate specificity and inhibitor analyses of human steroid 5β-reductase (AKR1D1) . Steroids . 2011 Apr ; 76 ( 5 ): 484 – 90 . Search in Google Scholar

32. Chen M, Drury JE, Christianson DW, Penning TM. Conversion of Human Steroid 5β-Reductase (AKR1D1) into 3β-Hydroxysteroid Dehydrogenase by Single Point Mutation E120H. Journal of Biological Chemistry. 2012 May 11;287(20):16609–22. Chen M Drury JE Christianson DW Penning TM. Conversion of Human Steroid 5β-Reductase (AKR1D1) into 3β-Hydroxysteroid Dehydrogenase by Single Point Mutation E120H . Journal of Biological Chemistry . 2012 May 11 ; 287 ( 20 ): 16609 – 22 . Search in Google Scholar